Aetion, the US-based creator of an analytics platform for drug developers, received $36.4m in funding yesterday from investors including Amgen Ventures, the corporate venturing vehicle for pharmaceutical company Amgen.
The series B round was led by venture capital firm New Enterprise Associates (NEA) and also featured healthcare investment firm Oxeon Ventures and VC firms Flare Capital Partners and Lakestar.
Aetion’s Evidence Platform combines data sourced from places such as health insurance claims, electronic health records, registries and clinical trials and uses analytics technology to generate insights concerning the effectiveness of medical treatments for pharmaceutical developers.
Elliott Levy, Amgen’s senior vice-president of research and development, said: “Amgen recognises the tremendous value of using real-world evidence to deliver innovative medicines to patients and physicians.
“Using Aetion’s Evidence Platform helps us inform our development efforts and improve our understanding of real-world practice patterns to ultimately enhance patient care.”
Mohamad Makhzoumi, global head of healthcare services for NEA, will join Aetion’s board of directors in connection with the round.
Aetion has now raised a total of $50m since it was founded in 2013. Flare Capital Partners led its $11.2m series A round in March 2017, investing alongside Lakestar.